Furthermore, in lupus nephritis, a combination therapy of tacrolimus and mycophenolate mofetil (a standard of care after KTx)33, had an additive protective effect for the podocyte actin cytoskeleton by tacrolimus-induced synaptopodin-mediated activation of RhoA and mycophenolate mofetil-mediated VAV1 inhibition of Rac132. This evidence concerns the gene VAV1 and lupus nephritis.